Scribd Logo
Încărcați

Bine ați venit la Scribd!

  • Results Press Release For March 31, 2016 (Result)

    Încărcat de

    Shyam Sunder
    4 vizualizări2 pagini
    This document is a press release from Aarti Drugs Limited announcing its financial results for the quarter ending March 2016. It states that while challenges from currency depreciation and economic factors in some key export markets continue, the company was still able to achieve 8.5% sales growth for the quarter. Consolidated EBITDA for the full year increased 3.55% to Rs. 175.69 crores. With higher capacity utilization, profits are expected to increase in the coming year. An expansion project that went live last quarter positively impacted domestic sales. The company is also upgrading its USFDA facility based on a recent audit.

    Descriere originală:

    Titlu original

    Results Press Release for March 31, 2016 [Result]

    Drepturi de autor

    © © All Rights Reserved

    Formate disponibile

    PDF, TXT sau citiți online pe Scribd

    Vi se pare util acest document?

    Este necorespunzător acest conținut?

    Raportați acest document
    This document is a press release from Aarti Drugs Limited announcing its financial results for the quarter ending March 2016. It states that while challenges from currency depreciation and economic factors in some key export markets continue, the company was still able to achieve 8.5% sales growth for the quarter. Consolidated EBITDA for the full year increased 3.55% to Rs. 175.69 crores. With higher capacity utilization, profits are expected to increase in the coming year. An expansion project that went live last quarter positively impacted domestic sales. The company is also upgrading its USFDA facility based on a recent audit.

    Drepturi de autor:

    © All Rights Reserved
    Descărcați ca PDF, TXT sau citiți online pe Scribd
    Indicator pentru conținut neadecvat
    4 vizualizări2 pagini

    Results Press Release For March 31, 2016 (Result)

    Încărcat de

    Shyam Sunder
    This document is a press release from Aarti Drugs Limited announcing its financial results for the quarter ending March 2016. It states that while challenges from currency depreciation and economic factors in some key export markets continue, the company was still able to achieve 8.5% sales growth for the quarter. Consolidated EBITDA for the full year increased 3.55% to Rs. 175.69 crores. With higher capacity utilization, profits are expected to increase in the coming year. An expansion project that went live last quarter positively impacted domestic sales. The company is also upgrading its USFDA facility based on a recent audit.

    Drepturi de autor:

    © All Rights Reserved
    Descărcați ca PDF, TXT sau citiți online pe Scribd
    Indicator pentru conținut neadecvat
    din 2

    Corporate Office : Mahendra Industrial Estate,

    =D

    Aarti Drugs Li nited


    Manufacturerc olF: Bulk Drugs

    Chemicals

    Ground Floor, Plot No. 109-D, Road No. 29,


    Sion (East), Mumbai - 400022. (India)
    25 (30 Lines)
    44

    Tel.:

    EXI;i,

    websi
    CIN No.:137060MH1984P1C055433

    Ref. No.: ADL12-M1SE/2016


    Date : Sth May, 2016
    To,

    To.

    Department of cortrrorate service,


    BSE Ltd.
    Phir oze Jeej eebhoy Towers,
    Dalal Street, Mumtrai - 40O OO 1.
    BSE COpE - s24348

    National Stock Exchange of India Limited,


    "Exchange PIaza", Bandra - Kurla Complex,
    Bandra (E), Mumbai - 4OOOS1.
    NSE SYMBOL: AARTIDRUGS

    Dear Sir/Madam,
    Please find enclosed herewith
    Sth May, 2016.

    Please take note of the sarne on

    of the press release issued by the Company on

    r record.

    Thankjng you,
    Yours faithfully,
    FoT AARTI DRUGS LIMITED

    \ 3 (s*-^t?.,
    VIBHAV S. RANAD]E
    COMPAIiTY SDCRETARY
    Encl: as above.

    66

    COI

    OFFICER

    Corporate Office : Mahendra Industrial Estate,


    Ground Floor, Plot No. 109-D, Road No. 29,
    Sion (East), Mumbai - 40O OZZ. (India)
    Tel.:022-2407 2249 / 24Ot 9025 (30 Lines)
    Fax.: O22-24O7 3462 / 2407 Otq
    Email : admin@aartidrugs.com
    website : www.aartidrugs.com
    CIN No. : Ul7060MH 1984P1C055433

    Aarti Drugs Li ited


    Manufacturerc of : Bulk Drugs

    Chemicals

    r'l
    Depreciation of currencies. other
    rmic factors in some key export markets like
    Latin America, other oil producing
    tries continue to pose challenge for global trade.
    In
    spite of these challenges, compan. was able to achieve
    growth of 8.560/o for the Mar,l6

    quarter.

    Consolidated EBITDA for the year


    Mar' 16 is 17 5.69 crores, up by 3.55oA, indicating
    stable operational efliciency. With
    ving sales and higher capacity utilization, company
    should be able to increase its
    profitability in the coming year. Due to improved
    working capital cycle, company was able to reduce its
    Debt/Equity ratio.
    Expansion proj ect of anti-diarrheal rroduct, which
    went live in Dec,15 quarter, favourably
    impacted domestic sa.les of the Mar l6 quarter.
    Company is actively upgrading the USFDA
    facility with the help of remediati plan, based on recent
    audit conducted by USA based
    consultant.

    FoT

    AARTI DRUGS LIMITED


    n

    {&'J*'
    HARSHIT M. SAVLA
    JT. MANAGING DITRBCTOR

    S-ar putea să vă placă și